Hiroko Iijima

Nishinomiya-hama, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 270 publications

Medical therapy of MASLD - consequences of the paradigm shift from histology to non-invasive tests.

Medical therapy of MASLD - consequences of the paradigm shift from histology to non-invasive tests.

Journal: JHEP reports : innovation in hepatology

Published: February 23, 2026

Diagnostic Impact of Two-Dimensional Shear Wave Elastography for Liver Fibrosis: A Multicenter Retrospective Study.

Diagnostic Impact of Two-Dimensional Shear Wave Elastography for Liver Fibrosis: A Multicenter Retrospective Study.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: December 07, 2025

Attenuation imaging and hepatorenal index composite score for the noninvasive assessment of hepatic steatosis in chronic liver disease: a prospective multicenter study.

Attenuation imaging and hepatorenal index composite score for the noninvasive assessment of hepatic steatosis in chronic liver disease: a prospective multicenter study.

Journal: Journal of medical ultrasonics (2001)

Published: October 26, 2025

Enhanced fumarate production using high-density cultivation of Synechocystis sp. PCC 6803.

Enhanced fumarate production using high-density cultivation of Synechocystis sp. PCC 6803.

Journal: Microbial cell factories

Published: October 26, 2025

Effect of Butyrate-Producing Enterobacteria and Proton Pump Inhibitors on Advanced Hepatocellular Carcinoma Treatment With Durvalumab and Tremelimumab.

Effect of Butyrate-Producing Enterobacteria and Proton Pump Inhibitors on Advanced Hepatocellular Carcinoma Treatment With Durvalumab and Tremelimumab.

Journal: JGH open : an open access journal of gastroenterology and hepatology

Published: September 03, 2025

The Hepatic Steatosis Diagnostic Performance Using Attenuation Imaging With the Magnetic Resonance Imaging-Based Proton Density Fat Fraction as the Reference Standard: A Large, Prospective, Multicenter Cohort Study in Japan.

The Hepatic Steatosis Diagnostic Performance Using Attenuation Imaging With the Magnetic Resonance Imaging-Based Proton Density Fat Fraction as the Reference Standard: A Large, Prospective, Multicenter Cohort Study in Japan.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: July 17, 2025

Correction: VFMAP predicted hepatocellular carcinoma development in patients with chronic hepatitis C who were treated with direct-acting antiviral and achieved sustained virologic response.

Correction: VFMAP predicted hepatocellular carcinoma development in patients with chronic hepatitis C who were treated with direct-acting antiviral and achieved sustained virologic response.

Journal: Journal of medical ultrasonics (2001)

Published: April 06, 2025

Deep-Learning-Aided Quantification of Steatohepatitis-Associated Pathological Findings in Liver Specimens.

Deep-Learning-Aided Quantification of Steatohepatitis-Associated Pathological Findings in Liver Specimens.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: March 24, 2025

A Newly Launched Nationwide Database Revealed Real-World Evidence on Systemic Therapy for Unresectable Hepatocellular Carcinoma in Japan: Hepatoma Registry of Integrating and Aggregating Electronic Health Record (HERITAGE).

A Newly Launched Nationwide Database Revealed Real-World Evidence on Systemic Therapy for Unresectable Hepatocellular Carcinoma in Japan: Hepatoma Registry of Integrating and Aggregating Electronic Health Record (HERITAGE).

Journal: Liver cancer

Published: February 25, 2025

US Markers and Necroinflammation, Steatosis, and Fibrosis in Metabolic Dysfunction-associated Steatotic Liver Disease: The iLEAD Study.

US Markers and Necroinflammation, Steatosis, and Fibrosis in Metabolic Dysfunction-associated Steatotic Liver Disease: The iLEAD Study.

Journal: Radiology

Published: August 20, 2024

Reliable Performance of mALBI Grade-Based Risk Models for Predicting the Prognosis of Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab as First-Line Treatment: Comparative Analysis of 13 Risk Models.

Reliable Performance of mALBI Grade-Based Risk Models for Predicting the Prognosis of Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab as First-Line Treatment: Comparative Analysis of 13 Risk Models.

Journal: Journal of gastroenterology and hepatology

Published: July 31, 2024

Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab.

Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab.

Journal: Targeted oncology

Published: April 03, 2024

Showing 1-12 of 270

Last Updated: 09/26/2026